[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646650":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":11,"responsibleParty":26,"collaborators":11,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":33,"acronym":11,"eligibilityCriteria":34,"healthyVolunteers":30,"sex":35,"minAge":36,"maxAge":37,"enrollmentInfo":38,"targetDuration":11,"studyType":41,"phases":42,"briefSummary":44,"conditions":45,"keywords":11,"overallStatus":47,"whyStopped":11,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":11},{"fullName":5,"class":6},"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants will receive IMM2510 20.0 mg\u002Fkg(Q2W), will receive IMM27M 1.0 mg\u002Fkg (Q8W)","EXPERIMENTAL",null,[13],"Drug: IMM2510, IMM27M",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","IMM2510, IMM27M","Biological\u002FVaccine: IMM2510 IMM2510 administered intravenously once every 2 weeks ( 20 mg\u002Fkg Q2W). Biological\u002FVaccine: IMM01 IMM01 administered intravenously once every 2 weeks ( 1 mg\u002Fkg Q8W).",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Lianxin Liu","CONTACT","+86 0551-62284121","liulx@ustc.edu.cn",{"type":27,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100646650","phase-2-a-study-of-imm2510--imm27m-combination-therapy-in-patients-with-advanced-hepatocellular-carcinoma-100646650",false,"NCT07687914","A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma","Phase II Clinical Study of IMM2510 for Injection Combined With IMM27M for Injection in Advanced Hepatocellular Carcinoma","Inclusion Criteria:\n\nParticipant has provided informed consent prior to initiation of any study specific activities\u002Fprocedures.\n\n* Age greater than or equal to 18 years old and ≤ 75 years old at the same time of signing the informed consent.\n* Histologically or cytologically confirmed for HCC\n* Eastern Cooperative Oncology Group (ECOG) 0 to 1.\n* Adequate organ function as defined in protocol.\n\nExclusion Criteria:\n\n* History of other malignancy within the past 5 years with exceptions.\n\n  * Systemic chemotherapy was administered within 4 weeks prior to the first administration.\n  * Activated symptomatic brain metastases and leptomeningeal disease.\n  * History of hepatic encephalopathy disease in past 12 months.\n  * Participants with symptoms and\u002For clinical signs and\u002For uncontrolled active systemic infection within 14 days prior to the first dose of study treatment. Participant has known active infection requiring parenteral antibiotic treatment.","ALL","18 Years","75 Years",{"count":39,"type":40},50,"ESTIMATED","INTERVENTIONAL",[43],"PHASE2","This is a Phase 2, open-label, multicenter,study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of IMM2510(Anti-PD-L1 and VEGF trap recombinant - Page 1 of 5 - protein) combine with IMM27M(Anti-CTLA-4 Humanized monoclonal antibody) in patients with advanced hepatocellular carcinoma who not have received the treatment for aHCC in past",[46],"HCC - Hepatocellular Carcinoma","NOT_YET_RECRUITING","2026-06-30",{"date":50,"type":51},"2026-07-07","ACTUAL",{"date":53,"type":40},"2026-07-23",{"date":55,"type":40},"2028-07-23",{"name":5,"class":6}]